Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (10665)	11/3/1997 9:47:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

TD, I don't have enough details. Rezulin is a first generation TZD and is taken at high doses (200 mg to 600 mg). Drugs at high concentrations can cause liver problems. SBH's TZD is taken at about 1/10 of the concentration (and I suspect that Takeda's second generation compound is also used at lower levels). Targretin has been shown to synergize with SBH's and Takeda's TZD and of course LGND has their own TZD program. One of the benefits of synergization is the ability to use each component at a lower level, so the Rezulin problems may be a plus for LGND (diabetics without the complications love Rezulin).

To: Arthur Radley who wrote (10665)	11/3/1997 10:07:00 AM
From: Henry Niman	Respond to of 32384

TD, LGND bid raised to 15 1/8 as MMs look for sellers.

To: Arthur Radley who wrote (10665)	11/3/1997 10:12:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

TD, CNBC just reported that WLA agreed to change Rezulin label to include a warning that Rezulin could cause idiosyncratic liver problems. Letter went to physicians on Friday.